# PATIENT REPORTED ADVERSE PSYCHOSOCIAL OUTCOMES AND IDENTIFICATION OF PREDICTIVE FACTORS IN THOSE WITH LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA

An analysis of the Lymphoma Coalition's 2024 Global Patient Survey

Steve E Kalloger<sup>1</sup>, Amanda Watson, BS<sup>2</sup>, Shawn Sajkowski, BS<sup>2</sup>, Lorna Warwick, BA<sup>2</sup> Las Vegas<sup>1</sup>, NV, USA, <sup>2</sup>Lymphoma Coalition, Mississauga, ON, Canada

Presented by: Lorna Warwick | CEO Lymphoma Coalition





#### INTRODUCTION

- Many Adverse Psychosocial Outcomes (APSOs) are frequently overlooked in clinical settings and are not consistently identified or documented through traditional Patient-Reported Outcome Measures (PROMs).
- This presentation draws on data from the 2024 Global Patient Survey on Lymphomas & CLL to explore 19 Adverse Psychosocial Outcomes (APSOs) and their associations with demographic and treatment-related factors.
- The findings highlight often-overlooked aspects of the cancer journey, including fear, emotional wellbeing, and social disruption.



Psychosocial outcomes extend beyond anxiety and depression and deserve deeper exploration.



#### **OBJECTIVES**



Measure the prevalence of 19 distinct APSOs amongst a patient population.



Explore associations with key variables: age, sex, time since diagnosis/ treatment, and relapse status.



Provide evidence to inform future PROM refinement and psychosocial care strategies.



Generate actionable insights that can inform more holistic, patient-centred outcome measures.



#### **METHODS**



6,073

**SURVEY RESPONSES** 



67


**COUNTRIES** 




- Cross-sectional anonymous survey conducted in early 2024, available in 20 languages.
- Population: individuals diagnosed with lymphoma or CLL.
- Predictors: age, biological sex, relapse status, time since last treatment and diagnosis.
- Nominal logistic regression used to model APSO prevalence.



#### APSO Prevalence - Top 10 Outcomes





#### All APSO Prevalence

APSOs span
emotional, existential,
and social dimensions
— not just clinical
symptoms.

#### The three least prevalent were:

Conflict between beliefs and cancer treatments: 2% (144)


Changes in faith or beliefs: 4% (260)

Post-traumatic stress disorder (PTSD): 9% (549)



#### Age Distribution of Respondents

Median age: 64 years (range: 18–92) 60% female - 40% male





Patients aged 55+
make up ~65% of
the sample, offering
insight across the
lifespan.

### **APSO Categories**

APSOs encompass emotional, existential, and social challenges.

Many respondents reported more than one APSO concurrently





## Predictive Patterns from Regression Analysis

- Age was found to be the most significant predictor in the regression analysis (p<0.0001), with an inverse relationship — younger patients had a higher risk of APSOs.
- No statistically significant associations were observed with sex.
- Fear of being immunocompromised had no significant association with age (p=0.4).

Age should be considered a key variable for psychosocial screening and intervention.

Patient-reported outcome measures and models of care should be adapted to

reflect this reality.

#### Younger Patient Burden

- Younger age was significantly associated with higher risk of multiple APSOs, including fear of relapse, anxiety, self-esteem loss, and isolation.
- Findings support the need for early intervention and age-sensitive mental health support.

Younger patients face a higher psychosocial burden, especially around fear, anxiety, and identity.

#### Key Takeaways

**APSOs** go beyond anxiety Age is a consistent  $( \vee )$ and depression predictive factor 01 03 04 PROMs should Widely experienced reflect the full across patient patient experience populations

#### Implications for Practice and Policy

**DATA** 

**INSIGHT** 

**ACTION** 

Prevalence and predictors of APSOs, particularly age.

Younger age = higher
psychosocial burden.
Younger individuals
consistently reported higher
levels of psychosocial
challenges across most APSOs.

Adjust PROMs and care models by age and scope.
PROMs should be agesensitive and capture a wider range of APSOs beyond anxiety and depression, to better inform psychosocial interventions and reflect patients' lived experiences.

PROMs must expand to reflect broader psychosocial realities, with younger patients prioritised for screening and results informing HTA decisions and care delivery models.





lymphomacoalition.org





